The CHMP has recommended granting a marketing authorization for Pfizer’s Abrysvo (bivalent, recombinant), a vaccine to protect against disease caused by the respiratory syncytial virus (RSV). Abrysvo is… read more.
GSK plc announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Arexvy (respiratory syncytial virus vaccine, adjuvanted) for active immunisation for the prevention of lower… read more.
GSK announced that the European Commission has authorised Arexvy (respiratory syncytial virus vaccine, adjuvanted) for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by… read more.
Experts have called for further scrutiny of a new Pfizer vaccine given during pregnancy to prevent respiratory infection in infants, after trials of a similar GSK vaccine were stopped… read more.
With what some are calling a “tripledemic” of COVID-19, the influenza virus and respiratory syncytial virus, or RSV, soaring in many parts of the country, the holiday season… read more.
Peer-reviewed/Literature review and Modelling/People Acute lower respiratory infection caused by Respiratory Syncytial Virus (RSV) contributes substantially to the global mortality burden in children, with RSV estimated to cause one… read more.
Nearly one in ten of all deceased infants under 6 months old were infected with Respiratory Syncytial Virus. A new study found that nearly one in ten of… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
